Arbutamine

Summary

Arbutamine (CHEMBL1201251) is an approved small-molecule β-adrenergic agonist (ATC C01CA22); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01CA22
• Indications: 1 condition
• Chemistry: 317.4 Da · C18H23NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201251
Name	Arbutamine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	60789
ChEBI	CHEBI:50580
ATC	C01CA22
Molecular formula	C18H23NO4
Molecular weight	317.4
InChIKey	IIRWWTKISYTTBL-SFHVURJKSA-N

SMILES: C1=CC(=CC=C1CCCCNC[C@@H](C2=CC(=C(C=C2)O)O)O)O

IUPAC name: 4-[(1R)-1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol

Pharmacological roles (ChEBI): β-adrenergic agonist, cardiotonic drug.

Also known as: Arbutamina, Arbutamine, ARBUTAMINE

Parent form; salt/anhydrous children: CHEMBL1200385

Patent coverage: 250 distinct patent families (838 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 835 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).